Trauma Monthly

Published by: Kowsar

Denosumab and Atypical Femoral Fractures: A Scoping Literature Review

Ammar Ismail 1 , Amira Hassan Bekhet 2 , Abdelrahman Ibrahim Abushouk 3 , 4 , * , Sahar Mirbaha 5 and Alireza Baratloo 6
Authors Information
1 Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2 Faculty of Physical Therapy, Cairo University, Cairo, Egypt
3 Faculty of Medicine, Ain Shams University, Cairo, Egypt
4 NovaMed Medical Research Association, Cairo, Egypt
5 Department of Emergency Medicine, Imam Hosein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Trauma Monthly: January 2018, 23 (1); e42869
  • Published Online: March 1, 2017
  • Article Type: Review Article
  • Received: October 7, 2016
  • Accepted: February 15, 2017
  • DOI: 10.5812/traumamon.42869

To Cite: Ismail A, Hassan Bekhet A, Ibrahim Abushouk A, Mirbaha S, Baratloo A. Denosumab and Atypical Femoral Fractures: A Scoping Literature Review, Trauma Mon. 2018 ; 23(1):e42869. doi: 10.5812/traumamon.42869.

Copyright © 2017, Trauma Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. doi: 10.1002/jbmr.1998. [PubMed: 23712442].
  • 2. Barcsa C, Endes J, Szappanos L. [Atypical fatigue fractures]. Beitr Orthop Traumatol. 1978;25(10):578-82. [PubMed: 728040].
  • 3. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008;39(2):224-31. doi: 10.1016/j.injury.2007.08.036. [PubMed: 18222447].
  • 4. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010;21(3):399-408. doi: 10.1007/s00198-009-0962-6. [PubMed: 19484169].
  • 5. Desai PA, Vyas PA, Lane JM. Atypical femoral fractures: a review of the literature. Curr Osteoporos Rep. 2013;11(3):179-87. doi: 10.1007/s11914-013-0167-y. [PubMed: 24048722].
  • 6. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48(5):966-71. doi: 10.1016/j.bone.2010.12.033. [PubMed: 21195812].
  • 7. Martinet O, Cordey J, Harder Y, Maier A, Buhler M, Barraud GE. The epidemiology of fractures of the distal femur. Injury. 2000;31 Suppl 3:C62-3. [PubMed: 11052383].
  • 8. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65. doi: 10.1056/NEJMoa0809493. [PubMed: 19671655].
  • 9. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther. 2012;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. [PubMed: 22440513].
  • 10. Simon JA, Recknor C, Moffett AJ, Adachi JD, Franek E, Lewiecki EM, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20(2):130-7. doi: 10.1097/gme.0b013e318267f909. [PubMed: 23010883].
  • 11. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27(9):2835-44. doi: 10.1007/s00198-016-3607-6. [PubMed: 27120345].
  • 12. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas. 2010;66(2):182-6. doi: 10.1016/j.maturitas.2010.02.008. [PubMed: 20236778].
  • 13. Ramchand SK, Chiang CY, Zebaze RM, Seeman E. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report. Osteoporos Int. 2016;27(2):821-5. doi: 10.1007/s00198-015-3354-0. [PubMed: 26458389].
  • 14. Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2015;26(1):361-72. doi: 10.1007/s00198-014-2871-6. [PubMed: 25236877].
  • 15. Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthop. 2014;85(1):1. doi: 10.3109/17453674.2013.859423. [PubMed: 24171676].
  • 16. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. [PubMed: 26202488].
  • 17. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483-92. doi: 10.1210/jc.2013-1597. [PubMed: 23979955].
  • 18. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291-9. doi: 10.1097/AOG.0b013e318291718c. [PubMed: 23812464].
  • 19. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161-9. doi: 10.1210/jc.2012-1569. [PubMed: 22723310].
  • 20. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227-35. doi: 10.1007/s00198-012-2052-4. [PubMed: 22776860].
  • 21. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-26. doi: 10.1007/s00198-011-1780-1. [PubMed: 21927922].
  • 22. Selga J, Nunez JH, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int. 2016;27(2):827-32. doi: 10.1007/s00198-015-3355-z. [PubMed: 26501556].
  • 23. Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone. 2014;61:44-7. doi: 10.1016/j.bone.2013.12.027. [PubMed: 24389366].
  • 24. Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014;85(1):3-5. doi: 10.3109/17453674.2013.854668. [PubMed: 24171686].
  • 25. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop. 2014;85(1):6-7. doi: 10.3109/17453674.2014.885355. [PubMed: 24460109].
  • 26. Paparodis R, Buehring B, Pelley EM, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract. 2013;19(3):e64-8. doi: 10.4158/EP12367.CR. [PubMed: 23337161].
  • 27. Ohnaru K, Kawamoto T, Yamamoto Y, Tanaka K, Mitani S, Hasegawa T. Atypical Femoral Fracture in a Patient with Metastatic Breast Cancer During Denosumab Therapy. J Clin Case Rep. 2016:201.
  • 28. Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013;2013:249872. doi: 10.1155/2013/249872. [PubMed: 24490096].
  • 29. Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55(2):495-500. doi: 10.1016/j.bone.2013.02.004. [PubMed: 23419776].
  • 30. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055-61. doi: 10.1124/jpet.102.035295. [PubMed: 12183663].
  • 31. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346-50. doi: 10.1097/BOT.0b013e318172841c. [PubMed: 18448990].
  • 32. Toro G, Ojeda-Thies C, Calabro G, Toro G, Moretti A, Guerra GM, et al. Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord. 2016;17:227. doi: 10.1186/s12891-016-1086-8. [PubMed: 27215972].
  • 33. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728-37. doi: 10.1056/NEJMoa1010650. [PubMed: 21542743].
  • 34. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-88. doi: 10.1359/jbmr.081206. [PubMed: 19049336].
  • 35. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52(1):360-5. doi: 10.1016/j.bone.2012.10.006. [PubMed: 23072919].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments